GGrantIndex
← Leaderboards

David Feldser

University Of Pennsylvania

$8,736,307
Attributed
$9,720,795
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY201125
$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,720,795 · 8

By mechanism

R01$8,395,637 · 5
R00$707,037 · 1
R21$384,921 · 1
K99$233,200 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Others in their field

Top investigators on “Molecular

Research focus

MolecularTumorMalignant NeoplasmsCellsGene ExpressionIn VivoProgramsPathway InteractionsGenesMouse ModelNeoplastic CellMediatingTumor Suppressor ProteinsMalignant Neoplasm Of LungSignal TransductionRestorationTumor SuppressionMutationInsightGenetically Engineered MouseCancer CellInnovationLung AdenocarcinomaGene Function

Grant awards (28)

Protein kinase C and lung carcinogenesis$653,908
R01 · FY2025 · CA
Context dependent tumor suppression$454,922
R01 · FY2025 · CA · contact PI
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma$434,444
R01 · FY2025 · CA · contact PI
Protein kinase C and lung carcinogenesis$640,695
R01 · FY2024 · CA
Context dependent tumor suppression$454,922
R01 · FY2024 · CA · contact PI
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma$410,628
R01 · FY2024 · CA · contact PI
Protein kinase C and lung carcinogenesis$674,373
R01 · FY2023 · CA
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma$439,136
R01 · FY2023 · CA · contact PI
Identifying the Impact of SETD2 Inactivation in Lung Adenocarcinoma$445,882
R01 · FY2022 · CA · contact PI
Deconstructing the multi-faceted roles of Rb in tumor progression$360,922
R01 · FY2022 · CA · contact PI
Deconstructing the multi-faceted roles of Rb in tumor progression$368,288
R01 · FY2021 · CA · contact PI
Deconstructing the multi-faceted roles of Rb in tumor progression$368,288
R01 · FY2020 · CA · contact PI
Deconstructing the multi-faceted roles of Rb in tumor progression$357,238
R01 · FY2019 · CA · contact PI
p53-Mediated Tumor Immune Surveillance$355,019
R01 · FY2019 · CA · contact PI
p53-Mediated Tumor Immune Surveillance$71,240
R01 · FY2019 · CA · contact PI
Deconstructing the multi-faceted roles of Rb in tumor progression$368,288
R01 · FY2018 · CA · contact PI
p53-Mediated Tumor Immune Surveillance$366,000
R01 · FY2018 · CA · contact PI
p53-Mediated Tumor Immune Surveillance$73,444
R01 · FY2018 · CA · contact PI
p53-Mediated Tumor Immune Surveillance$366,000
R01 · FY2017 · CA · contact PI
Identifying Mechanisms of p53 and Rb Tumor Suppression In Small Cell Lung Cancer$210,105
R21 · FY2017 · CA · contact PI
p53-Mediated Tumor Immune Surveillance$366,000
R01 · FY2016 · CA · contact PI
Identifying Mechanisms of p53 and Rb Tumor Suppression In Small Cell Lung Cancer$174,816
R21 · FY2016 · CA · contact PI
p53-Mediated Tumor Immune Surveillance$366,000
R01 · FY2015 · CA · contact PI
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression$236,784
R00 · FY2015 · CA · contact PI
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression$236,194
R00 · FY2014 · CA · contact PI
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression$234,059
R00 · FY2013 · CA · contact PI
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression$116,600
K99 · FY2012 · CA · contact PI
Establishing therapeutic efficacy and uncovering mechanisms of tumor suppression$116,600
K99 · FY2011 · CA · contact PI